Prognostic value of perfusion MR imaging in patients with oligodendroglioma: A survival study

✍ Scribed by Z. Jiang; J.-F. Le Bas; S. Grand; C. Salon; C. Pasteris; D. Hoffmann; F. Bing; F. Berger; S. Chabardes; C. Liu; A. Krainik

• Publisher: Masson Editeur
• Year: 2011
• Tongue: English
• Weight: 549 KB
• Volume: 38
• Category: Article
• ISSN: 0150-9861
• DOI: 10.1016/j.neurad.2010.03.004

✦ Synopsis

The purpose of this study was to evaluate retrospectively whether cerebral blood volume measurement based on pretreatment perfusion MRI is a prognostic biomarker for survival in patients with oligodendroglioma or mixed oligoastrocytoma. Patients and methods. -Between 1998 and 2004, 54 patients (23 females and 31 males), aged 21-73 years, with oligodendroglioma (or mixed tumour) were examined prior to beginning treatment with dynamic susceptibility-weighted contrast (DSC) perfusion MRI during gadolinium first-pass. The relative cerebral blood volume (rCBV) was calculated by dividing the measurement within the tumour by the measurement of the normal-appearing contralateral region. Patients were classified in two groups, grade A and grade B, according to the Saint-Anne Hospital classification and followed-up clinically and by means of MRI until their death or for a minimum of 5 years. Patients were also classified in grade II and grade III-IV, according to the World Health Organisation (WHO) classification, and were analysed with the same methods. Age, sex, treatment, tumour grade, contrast agent uptake, and rCBV were tested using survival curves with Kaplan-Meier's method, and their differences were analysed using the log-rank test.